Opko Health (OPK) : Jaffetilchin Investment Partners scooped up 33,435 additional shares in Opko Health during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 14, 2016. The investment management firm now holds a total of 445,268 shares of Opko Health which is valued at $4,808,894.Opko Health makes up approximately 1.51% of Jaffetilchin Investment Partners’s portfolio.
Opko Health opened for trading at $10.87 and hit $11.08 on the upside on Monday, eventually ending the session at $11.05, with a gain of 2.31% or 0.25 points. The heightened volatility saw the trading volume jump to 28,66,999 shares. Company has a market cap of $6,032 M.
Other Hedge Funds, Including , Simplex Trading boosted its stake in OPK in the latest quarter, The investment management firm added 51,296 additional shares and now holds a total of 51,496 shares of Opko Health which is valued at $556,157. Opko Health makes up approx 0.09% of Simplex Trading’s portfolio.Edge Wealth Management reduced its stake in OPK by selling 900 shares or 36.75% in the most recent quarter. The Hedge Fund company now holds 1,549 shares of OPK which is valued at $16,652. Opko Health makes up approx 0.01% of Edge Wealth Management’s portfolio. Proficio Capital Partners added OPK to its portfolio by purchasing 36 company shares during the most recent quarter which is valued at $387.Rk Asset Management boosted its stake in OPK in the latest quarter, The investment management firm added 10,960 additional shares and now holds a total of 935,822 shares of Opko Health which is valued at $10,060,087. Opko Health makes up approx 8.58% of Rk Asset Management’s portfolio.
On the company’s financial health, Opko Health reported $0.25 EPS for the quarter, beating the analyst consensus estimate by $ 0.26 according to the earnings call on Nov 9, 2015. Analyst had a consensus of $-0.01. The company had revenue of $143.00 million for the quarter, compared to analysts expectations of $133.04 million. The company’s revenue was up 622.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.11 EPS.
Many Wall Street Analysts have commented on Opko Health. Shares were Reiterated by Barrington Research on Mar 31, 2016 to “Outperform” and Lowered the Price Target to $ 16 from a previous price target of $17 .
OPKO Health Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose treat and prevent various conditions including point-of-care tests laboratory developed tests (LDTs) molecular diagnostics tests and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile Spain Mexico Israel Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.